Initial treatment of renal allografts with large intrarenal doses of immunosuppressive drugs

Kountz, Samuel L.; Ra, Cohn

doi:10.1097/00007890-196910000-00034

Cited by 10 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,8,9 Renal involvement was seen in 35% in our study in concordance with other studies where it was between 21.4%-67%. 4 The cutaneous feature to show an early response was oral erosions which resolved after a mean of 2.3 pulses in our study. A similar figure of 1-3 pulses has been reported by Dhabhai et al 8 The percentage improvement was 88%.…”

Section: Discussionsupporting

confidence: 51%

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

2016

View full text Add to dashboard Cite

Background: Systemic lupus erythematosus (SLE) is always a challenge to the treating dermatologists. Pulse therapy is the use of supra pharmacological doses of drugs to achieve a desired therapeutic effect. The success of dexamethasone cyclophosphamide pulse therapy (DCP) in autoimmune bullous diseases has prompted dermatologists to use DCP in SLE but very few studies are available which objectively measure the outcome of DCP therapy in SLE. The aim of our study is to study the efficacy of dexamethasone cyclophosphamide pulse in patients with SLE and to use objective scoring systems to assess efficacy.Methods: 20 SLE patients who satisfied the inclusion criteria were administered intravenous dexamethasone 100 mg over three days with cyclophosphamide 500 mg on day1, followed by oral cyclophosphamide 50 mg daily. In patients whom cyclophosphamide cannot be used oral azathioprine was given. Response to treatment was assessed using CLASI (cutaneous lupus area severity index), clinical evaluation of dermatological and systemic symptoms and laboratory parameters such as ANA, Anti dsDNA, ESR etc.Results: All the patients showed clinical improvement with statistically significant fall in CLASI scores and anti dsDNA values. The mean duration of pulses required to achieve remission was 9 pulses. No major adverse effects were observed in any of the patients.Conclusions: Dexamethasone cyclophosphamide pulse therapy is an effective and safe option in the management of patients with SLE.

show abstract

Section: Discussionsupporting

confidence: 51%

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

2016

View full text Add to dashboard Cite

show abstract

“…Pulses of méthylprednisolone were first successfully used in the late 1960s in patients undergoing renal trans plantation [13). Pulse therapy was also effectively used to treat systemic polyarteritis [14), rheumatoid arthritis [15], rheumatic disease of children and dermatologic disorders such as pyoderma gangrenosum [17], lichen planus [18], pemphigus vulgaris [pers.…”

Section: Discussionmentioning

confidence: 99%

“…Among them, systemic corticosteroids have been shown to be the most effective but carry the risks of severe side effects in long-term therapy. In order to decrease the side effects and improve the efficiency of corticosteroids, high doses of méthylprednisolone in bolus have been used to treat renal allografts, autoimmune or inflammatory dis eases [13][14][15]. In 1975, Burton and Shuster [ 16] used a sin gle 2-gram intravenous méthylprednisolone pulse in 22 patients with AA with little success.…”

Section: Introductionmentioning

confidence: 99%

Pulse of Methylprednisolone in Alopecia areata

Perriard-Wolfensberger

Pasche-Koo

Mainetti

et al. 1993

Dermatology

View full text Add to dashboard Cite

In an attempt to stop the evolution of recent-onset severe alopecia areata (AA), we tested pulse corticotherapy on 9 patients. Acceptance into the study was based on the following criteria: recent-onset AA (< l year), AA in an active state, bald surface > 30% of the scalp, no contraindication to pulse corticotherapy. Each patient was given 250 mg i.v. of methylprednisolone twice a day on 3 successive days. In 8 patients the course of the ongoing episode of AA was stopped. At the 6-month follow-up, a regrowth on 80–100% of the bald surface was observed in 6 patients. One patient did not respond to treatment, and 2 had less than 50% of regrowth. This open study suggests that pulse corticotherapy: (1) can stop the course of severe AA in an active state, (2) is well tolerated without major side effects and (3) does not permit a stable control of AA of more than 1 year duration. This treatment seems to be indicated for severe AA of recent onset.

show abstract

“…After the report by Kountz and Cohn [7], who prescribed pulse therapy for acute rejec tion in renal transplantation, many clini cians attempted to treat severe immunolog ical disorders including rapidly progressive glomerulonephritis [2], lupus nephritis [6] and polyarteritis nodosa [10] with high-dose méthylprednisolone.…”

Section: Discussionmentioning

confidence: 99%

Methylprednisolone Pulse Therapy in Dermatomyositis

Yanagisawa¹,

Sueishi²,

Nawata³

et al. 1983

Dermatology

View full text Add to dashboard Cite

A high dose of methylprednisolone (pulse therapy) was given to 3 patients with uncontrolled dermatomyositis (DM) accompanied by severe muscle weakness. The effects of pulse therapy were compared with findings in 5 patients with severe DM who were treated with the usual dose of prednisolone (controls). The pulse therapy led to an improvement in the clinical symptoms in the 3 patients with uncontrolled DM, who were in danger of aspiration pneumonia. A rapid reduction in muscle enzyme levels in this group was also evident.

show abstract

Initial treatment of renal allografts with large intrarenal doses of immunosuppressive drugs

Cited by 10 publications

References 0 publications

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

Study of dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus

Pulse of Methylprednisolone in Alopecia areata

Methylprednisolone Pulse Therapy in Dermatomyositis

Contact Info

Product

Resources

About